Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Physiomics ( (GB:PYC) ) just unveiled an announcement.
Physiomics plc has secured a new contract from long-standing client Numab Therapeutics AG to develop a pharmacokinetic-pharmacodynamic (PK/PD) model for a key asset in Numab’s immunology and inflammation pipeline, reinforcing its role as a specialist partner in quantitative drug development. The project, which is due to start immediately and conclude by the second quarter of 2026, will inform the target candidate profile at an early stage to support data-driven R&D decisions, deepening the companies’ collaboration and highlighting the growing reliance of next-generation antibody developers on advanced modelling to accelerate and de-risk pipeline progression.
The most recent analyst rating on (GB:PYC) stock is a Hold with a £0.27 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Neutral.
The score is held back primarily by weak financial performance (continued losses and cash burn despite revenue growth) and a bearish technical setup (below major moving averages with negative MACD). Offsetting factors include a clean, no-debt balance sheet and positive corporate updates around new/follow-on contracts and team retention, but these are not yet reflected in profitability or cash generation.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a UK-based mathematical modelling, data science, biostatistics and bioinformatics specialist that helps biotech and pharmaceutical companies streamline drug development across discovery, pre-clinical and clinical stages. Leveraging bespoke computational models and its proprietary Virtual Tumour technology, the company integrates disparate biological and clinical data to de-risk decision-making and optimise research design, and has supported more than 140 commercial projects for clients including Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.
Average Trading Volume: 3,401,567
Technical Sentiment Signal: Sell
Current Market Cap: £849K
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.